<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04250350</url>
  </required_header>
  <id_info>
    <org_study_id>17804</org_study_id>
    <secondary_id>J2T-DM-KGAE</secondary_id>
    <secondary_id>DRM06-AD17</secondary_id>
    <nct_id>NCT04250350</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis</brief_title>
  <acronym>ADore</acronym>
  <official_title>An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dermira, Inc. a wholly owned subsidiary of Eli Lilly and Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single arm study of 52 weeks duration. The study will assess the
      safety and efficacy of lebrikizumab in adolescent patients age 12 years and above, weighing
      at least 40 kg, with moderate to severe atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 22, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events from Baseline to Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events from Baseline to Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Lebrikizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Q2W</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lebrikizumab</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Lebrikizumab</arm_group_label>
    <other_name>LY3650150</other_name>
    <other_name>DRM06</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adolescent (≥12 years to 17 years, and weighing ≥40 kg).

          2. Chronic AD (according to American Academy of Dermatology Consensus Criteria) that has
             been present for ≥1 year before the screening visit.

          3. Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit.

          4. Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit

          5. ≥10% body surface area (BSA) of AD involvement at the baseline visit.

          6. History of inadequate response to treatment with topical medications; or determination
             that topical treatments are otherwise medically inadvisable.

        Exclusion Criteria:

          1. Participation in a prior lebrikizumab clinical study.

          2. Treatment with the following prior to the baseline visit:

               1. An investigational drug within 8 weeks or within 5 half-lives (if known),
                  whichever is longer.

               2. Dupilumab within 8 weeks.

               3. Cell-depleting biologics, including to rituximab, within 6 months.

               4. Other biologics within 5 half-lives (if known) or 16 weeks, whichever is longer.

          3. Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or
             planned during the study.

          4. Uncontrolled chronic disease that might require bursts of oral corticosteroids.

          5. Evidence of active acute or chronic hepatitis

          6. History of human immunodeficiency virus (HIV) infection or positive HIV serology at
             screening.

          7. History of malignancy, including mycosis fungoides, within 5 years before the
             screening visit, except completely treated in situ carcinoma of the cervix, completely
             treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.

          8. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Research Trials, LLC</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>847-721-2725</phone>
    </contact>
    <investigator>
      <last_name>Aaron Farberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Studies</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>714-241-1332</phone>
    </contact>
    <investigator>
      <last_name>Ronald Schilling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tien Q. Nguyen, MD inc. DBA First OC Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>714-531-2966</phone>
    </contact>
    <investigator>
      <last_name>Vivian Thuy-Vy Laquer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern California Dermatology</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>714-474-2173</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Soung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Solutions Through Advanced Research, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>904-619-8157</phone>
    </contact>
    <investigator>
      <last_name>Pearl Chu Kwong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acevedo Clinical Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>786-212-4187</phone>
    </contact>
    <investigator>
      <last_name>Armando E Acevedo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Well Pharma Medical Research Corp.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>305-665-4818</phone>
    </contact>
    <investigator>
      <last_name>Eddie Armas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>812-264-2155</phone>
    </contact>
    <investigator>
      <last_name>Seth Benjamin Forman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Pollens Clinical Research Centers, Inc</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>229-883-8909</phone>
    </contact>
    <investigator>
      <last_name>Tracy Bridges</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>4049399220</phone>
    </contact>
    <investigator>
      <last_name>Jamie Debra Weisman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>312-695-3721</phone>
    </contact>
    <investigator>
      <last_name>Amy Paller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>317-516-5030</phone>
    </contact>
    <investigator>
      <last_name>Scott A Fretzin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Sciences, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>502-451-9000</phone>
    </contact>
    <investigator>
      <last_name>Leon H Kircik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology and Skin Cancer Specialists</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>301-355-3183</phone>
    </contact>
    <investigator>
      <last_name>Benjamin N. Lockshin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Lakes Research Group, Inc.</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>989-895-9100</phone>
    </contact>
    <investigator>
      <last_name>Brent Michael Boyce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Joseph Dermatology and Vein Clinic</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>269-428-5199</phone>
    </contact>
    <investigator>
      <last_name>Vassilios Dimitropoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ALLCUTIS Research</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>603-319-8863</phone>
    </contact>
    <investigator>
      <last_name>Abel Jarell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Forest Hills Dermatology Group</name>
      <address>
        <city>Kew Gardens</city>
        <state>New York</state>
        <zip>11374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>718-459-0900</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Weinberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Asthma and Allergy</name>
      <address>
        <city>Watertown</city>
        <state>New York</state>
        <zip>13601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>315-681-4192</phone>
    </contact>
    <investigator>
      <last_name>Dariusz Chrostowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute, P.C.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>918-392-4550</phone>
    </contact>
    <investigator>
      <last_name>Iftikhar Hussain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OHSU Center for Health and Healing</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>503-494-3968</phone>
    </contact>
    <investigator>
      <last_name>Eric L Simpson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rivergate Dermatology Clinical Research Center PL</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>615-859-7546</phone>
    </contact>
    <investigator>
      <last_name>Keith Loven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>210-614-5557</phone>
    </contact>
    <investigator>
      <last_name>Mark S Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acclaim Dermatology, PLLC</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77497</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>(+1) 832-770-6388 Ext 106</phone>
    </contact>
    <investigator>
      <last_name>Syed Omar Ali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>757-625-0151</phone>
    </contact>
    <investigator>
      <last_name>David Michael Pariser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woden Dermatology</name>
      <address>
        <city>Phillip</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>(+61) 2 6282 8410</phone>
    </contact>
    <investigator>
      <last_name>Diana Marie Rubel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Skin Centre</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>(+61) 755977170</phone>
    </contact>
    <investigator>
      <last_name>Michael G Freeman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veracity Clinical Research Pty Ltd</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>61730391311</phone>
    </contact>
    <investigator>
      <last_name>Lynda Jane Spelman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>Victoria</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>(+61) 03 96542426</phone>
    </contact>
    <investigator>
      <last_name>Samantha Eisman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermoklinika Centrum Medyczne s.c. M. Kierstan J. Narbutt A. Lesiak</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aleksandra Lesiak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grazyna Pulka Specjalistyczny Osrodek &quot;ALL-MED&quot;</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>(+48) 124 223 171</phone>
    </contact>
    <investigator>
      <last_name>Grazyna Pulka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Rewerska DIAMOND CLINIC</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>(+48) 571241412</phone>
    </contact>
    <investigator>
      <last_name>Barbara Rewerska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Evimed</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-625</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Monika Slowinska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LASER CLINIC Specjalistyczne Gabinety Lekarskie</name>
      <address>
        <city>Szczecin</city>
        <state>Zachodniopomorskie</state>
        <zip>70-332</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Katarzyna Turek-Urasinska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>(+48) 815323647</phone>
    </contact>
    <investigator>
      <last_name>Dorota Krasowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CityClinic Przychodnia Lekarsko-Psychologiczna</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-566</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>(+48) 601534853</phone>
    </contact>
    <investigator>
      <last_name>Jacek Szepietowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ADvocatestudies.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 15, 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eczema</keyword>
  <keyword>Dermatitis</keyword>
  <keyword>Dermatitis, Atopic</keyword>
  <keyword>Skin Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

